Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin
Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin
复制标题
DOI：
10.1002/cncr.20727
复制
发表时间：
2005-01-01
期刊：
影响因子：
6.2
通讯作者：
Weiss, NS
中科院分区：
文献类型：
--
作者：
Chen, C;Lewis, SK;Weiss, NS
背景有几项流行病学研究调查了胰岛素样生长因子I（IGF-I）、胰岛素样生长因子结合蛋白3（IGFBP-3）和胰岛素循环水平与前列腺癌风险之间的关系，结果相互矛盾。为了进一步研究这一问题，作者在心血管健康研究队列中进行了一项巢式病例对照研究。在1990年至1999年期间诊断为前列腺癌的男性（病例）中（n = 174），在诊断前1-9年（平均3.4年）获得的血液样本中测量IGF-I，IGFBP-3和胰岛素水平。对174名没有前列腺癌的男性参与者（对照组）进行了类似的测量，这些参与者与基于抽血年份、诊断日期前的生存率、种族和年龄的病例相匹配。相对于IGF-I水平在分布的第一（最低）四分位数的男性，第二、第三和第四（上）四分位数的男性患前列腺癌的风险为0.77（95%置信区间[95% CI]，0.43-1.38）、0.73（95% CI，0.41-1.30）和0.67（95% CI，0.37-1.25）。调整IGFBP-3水平或评价IGF-I/IGFBP-3摩尔比对结果的影响很小。一项仅限于抽血时血浆前列腺特异性抗原水平< 4 ng/mL的男性的分析得出了类似的结果。IGFBP-3的相应相对风险分别为0.91（95%CI，0.49-1.68）、0.47（95%CI，0.25-0.94）和0.65（95%CI，0.35-1.20）。病例组与对照组血清胰岛素水平的分布基本一致。IGF-I水平与前列腺癌风险无正相关性;然而，IGFBP-3水平升高与风险适度降低相关。(C)2004年美国癌症协会。
BACKGROUND. There have been several epidemiologic studies investigating the association between circulating levels of insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 3 (IGFBP-3), and insulin in relation to the risk of prostate carcinoma, with conflicting results. To examine this issue further, the authors conducted a nested case-control study within the Cardiovascular Health Study cohort.METHODS. In men who were diagnosed with prostate carcinoma (cases) between 1990 and 1999 (n = 174), the levels of IGF-I, IGFBP-3, and insulin were measured on blood samples that were obtained 1-9 years prior to diagnosis (mean, 3.4 years). Similar measurements were made on 174 male participants without prostate carcinoma (controls) who were matched to cases based on the year blood was drawn, survival Until the date of diagnosis, race, and age.RESULTS. Relative to the men with IGF-I levels in the first (lowest) quartile of the distribution, the risk of prostate carcinoma for men in the second, third, and fourth (upper) quartiles were 0.77 (95% confidence interval [95% CI], 0.43-1.38), 0.73 (95% CI, 0.41-1.30), and 0.67 (95% CI, 0.37-1.25), respectively. The results were influenced little by adjustment for levels of IGFBP-3 or, instead, by evaluating the molar IGF-I/IGFBP-3 ratio. An analysis that was restricted to men who had plasma prostate-specific antigen levels < 4 ng/mL at the time of the blood draw yielded similar results. The corresponding relative risks for IGFBP-3 were 0.91 (95% CI, 0.49-1.68), 0.47 (95% CI, 0.25-0.94), and 0.65 (95% CI, 0.35-1.20), respectively. The distribution of serum insulin levels in cases and controls were nearly identical.CONCLUSIONS. The IGF-I level was not associated positively with the risk of prostate carcinoma; however, an increase in the IGFBP-3 level was associated with a modest decrease in risk. (C) 2004 American Cancer Society.